Startups

Siena Secondary Fund II is an alternative investment fund registered with the Estonian Financial Supervision Authority (FSA) and managed by Siena Venture Partners OÜ. The fund focuses on high-growth technology companies across the Baltics, Nordics, and Central & Eastern Europe, primarily through secondary transactions. Its strategy is to acquire stakes in promising companies with proven business models, unique technologies, and strong growth potential — often at a discount to fair market value. The fund targets a total size of €50 million, with investments ranging from €1–4 million per deal. It mainly invests in companies that are post-Series A or already at breakeven stage, generating €10M+ in annual revenue and growing by more than 50% annually. The fund aims for liquidity events within 3–5 years and targets a 3–5x return following successful exits. The investment pipeline is based on a longlist of more than 200 potential targets, including regional leaders such as Vinted, Infobip, Katana, AirHelp, Tuum, Einride, and other fast-scaling technology companies. The fund has a planned investment period of 3 years and a total term of 7 years, with possible extensions, providing flexibility to maximize value creation and long-term capital appreciation.

Feeder fund with diversified investments in cooperative and public money driven start-up investment funds.

Exonicus’s mission is to save lives by transforming how medical and defense professionals train for high-stakes situations. We develop state-of-the-art virtual reality simulators that allow first responders and clinicians to build and refine their skills in realistic, controlled environments - advancing readiness, education, and patient care.

Tournated is an all-in-one sports management software that empowers sports organizations to efficiently manage, grow, and monetize their operations.

Orbit8 revolutionizes career and education choices through a space-industry-inspired assessment. It offers tailored advice on study paths, industries, and work environments based on your strengths and preferences. With AI-driven suggestions, Orbit8 helps you discover the best-fitting job titles and opportunities.

Bonus Card provides a unique solution, allowing you to personalize a wide range of benefit categories designed to address the diverse needs of your employees. From meal allowances and healthcare options to transportation benefits and such wellness/well-being activities as spa treatments, fitness memberships, theatre tickets and access to bookstores, the Bonus Card makes it possible 24/7 across the globe. This level of flexibility not only boosts employee happiness but also strengthens their commitment to the organization.

The platform runs on 100% opt-in, privacy-safe player data (zero-party signals captured directly in gameplay). This enables precise targeting and measurable brand lift — all without relying on IDFA. Today, global CPG leaders such as Procter & Gamble, PepsiCo, and Haleon, along with publishers like Kwalee and Voodoo, utilise Monetizr to deliver immersive, rewarded brand experiences at scale.  Monetizr unifies three layers into one system: consented identity (audience), in-game delivery (rewarded formats), and built-in measurement (brand lift). The result: campaigns chosen by players, not forced — reaching the world’s 3.8 billion mobile gamers with brand experiences people actually want to engage with.

Cellbox Labs is pioneering next-generation organ-on-a-chip technologies. The company develops miniature, functional replicas of human organs outside the body, with a primary focus on gut- and microbiome-on-a-chip platforms. These systems provide powerful tools for accelerating drug discovery, improving therapeutic effectiveness, and enabling advanced studies of complex biological processes. To support widespread adoption, Cellbox Labs is also creating an easy-to-use instrument that allows researchers to efficiently run and analyze experiments directly on the chips, lowering barriers to entry and expanding the impact of organ-on-a-chip technology in biomedical research.

Ybil OÜ (TMS & eCMR) was founded by experienced carriers with the support of the Estonian Business and Innovation Agency. It is one of the first official eFTI (electronic freight transport information) platforms in Europe. Our target markets are the Baltic States, Scandinavia, the Western Balkans and the Gulf Cooperation Countries, but we are also open to working in other regions.

Rebookify was established with the goal of helping travel agencies increase profitability by reducing hotel booking costs. The company brings together experts from the travel industry and technology sector who developed a solution that is both powerful and user-friendly. The platform requires no complex setup or additional hardware, as it integrates directly with existing systems, enabling agencies to achieve savings immediately.

Cellbox Labs is pioneering next-generation organ-on-a-chip technologies. The company develops miniature, functional replicas of human organs outside the body, with a primary focus on gut- and microbiome-on-a-chip platforms. These systems provide powerful tools for accelerating drug discovery, improving therapeutic effectiveness, and enabling advanced studies of complex biological processes. To support widespread adoption, Cellbox Labs is also creating an easy-to-use instrument that allows researchers to efficiently run and analyze experiments directly on the chips, lowering barriers to entry and expanding the impact of organ-on-a-chip technology in biomedical research.

inGain's no-code SaaS loan management system enabling lenders and businesses in different sectors to launch and scale lending and financial products. Lenders may scale their business without the hassle of IT management. Non-finance industries may seamlessly integrate fintech products into their customer journey and unlock new business opportunities. All of this can be accomplished within just 2 weeks using our no-code SaaS loan management system.